Post by : Rameen Ariff

Washington — Tensions rose briefly at a White House event on Thursday led by President Donald Trump when a man fainted while standing behind the President during an announcement focusing on reducing the prices of weight-loss drugs. The gathering was halted for nearly an hour until medical personnel confirmed the individual's safety.

The incident unfolded as Eli Lilly's CEO, David Ricks, was discussing a new contract with the U.S. government aimed at lowering the costs of weight-loss medications. The fainting individual, a representative from a pharmaceutical firm, collapsed amidst other executives and officials behind the president's desk.

As the individual went down, Ricks was overheard asking, “You OK?” while others rushed to assist him. Attendees had reportedly been standing for approximately 30 minutes in the warm Oval Office prior to the incident.

Trump quickly left his desk to intervene while medical staff attended to the man. He was assessed by Mehmet Oz, head of the Centers for Medicare and Medicaid Services, who later assured that he was doing well.

“He got a little light-headed… You saw he went down. He’s fine,” Trump commented after the event resumed. “They just sent him out and he’s got doctors’ care.”

Following the incident, Ricks addressed the media, identifying the man as Gordon, a guest of Eli Lilly.

“He became faint — it’s warm and you stand a long time in the Oval Office,” Ricks mentioned. “The White House medical team did a great job. He’s doing great, nothing to worry about.”

Trump Unveils Weight-Loss Drug Pricing Changes

In conjunction with the incident, President Trump revealed significant price agreements with pharmaceutical leaders Eli Lilly and Novo Nordisk. This initiative aims to make prominent GLP-1 weight-loss drugs like Zepbound and Wegovy more financially accessible for American consumers.

“These companies have consented to offer their leading weight-loss drugs at significant discounts,” Trump stated. “This will provide much-needed relief for Americans seeking access to these life-enhancing medications.”

GLP-1 medications, including Ozempic, Wegovy, and Mounjaro, have increased in demand due to their efficacy in weight management, but their steep costs—often surpassing $1,000 monthly—have sparked concerns regarding affordability in the U.S.

This new agreement aims to offer lower prices while also alleviating tariff pressures on the pharmaceutical industry.

#Global News